Hitaxa Fast

Desloratadine

Method of action: Antiallergic, Antiexudative, Antihistamines For Systemic Use, Antipruritic, H1-Antihistamine

Treatment option: Jock Itch, Hives, Rhinitis, Hay Fever

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Hitaxa Fast

Property	Description
Active ingredient	Desloratadine
Form	Orally Disintegrating Tablet (ODT) or Tablet
Pharmacological class	H1-Receptor Antagonist (Second-Generation Antihistamine)
Common use	Symptom control for allergic conditions
Origin	Synthetic, Active metabolite of Loratadine

What Type of Medicine is Hitaxa Fast? (Identity and Classification)

Hitaxa Fast is a medicinal preparation whose active substance is Desloratadine (INN), classified as a Histamine H1-Receptor Antagonist. This compound belongs to the second-generation class of antihistamines, distinguished by its selective and peripheral action. It is designated as non-sedating because it avoids significant central nervous system penetration, a key differentiating factor from older antihistamines. The medicine is clinically recognized for its ability to provide a long-lasting effect, helping control allergic symptoms throughout a full day.

Composition, Form, and Origin (Chemical and Physical Nature)

The active ingredient, Desloratadine, is a synthetic compound derived from Loratadine, functioning as its major active metabolite, which is the precise chemical form that performs the body's therapeutic work. The "Fast" designation highlights a key differentiating feature: the drug is frequently available as an Orally Disintegrating Tablet (ODT) dosage form, which dissolves quickly on the tongue. This specific presentation is often preferred for rapid administration or for patient groups who may have difficulty swallowing standard tablets, making consumption easy without the need for water.

General Purpose: How Hitaxa Fast Helps Against Allergies (High-Level Benefit)

The general purpose of Hitaxa Fast is to provide symptom control and relief from physical discomforts associated with allergic conditions. The medicine achieves this through selective histamine blockade, directly preventing the binding and action of histamine—the chemical compound released by the body during an allergy. This mechanism is recognized for effectively managing common allergic manifestations like sneezing, nasal discharge, and itching. The consistent action makes it suitable for individuals requiring reliable relief for chronic conditions such as allergic rhinitis or chronic idiopathic urticaria (hives).

What side effects are possible with Hitaxa Fast?

Possible Side Effects and Safety Information

Hitaxa Fast (Desloratadine) is a second-generation antihistamine with a generally well-tolerated safety profile. In clinical trials at the recommended daily dose of 5 mg, adverse events occurred in approximately 3% of patients in excess of placebo.

Documented Adverse Reactions

Frequency Classification	Key Adverse Reactions (System Organ Class)
Common (May affect up to 1 in 10 people)	Fatigue, Dry Mouth, Headache (Nervous/General Disorders)
Very Rare (May affect up to 1 in 10,000 people)	Severe allergic reactions (anaphylaxis, angioedema), Seizures, Hallucinations, Tachycardia, Palpitations, Hepatitis, Jaundice, Elevations of liver enzymes, Myalgia, Vomiting, Diarrhoea (Multiple System Classes)
Not Known (Frequency cannot be estimated)	Abnormal behaviour, Aggression, Depressed mood, Slow heartbeat, Changes in heart rhythm (QT prolongation, arrhythmia, bradycardia), Photosensitivity, Weight increased, Increased appetite (Multiple System Classes)

Clinically Significant Safety Considerations

Serious Reactions: Rare but serious adverse reactions documented in post-marketing reports include severe hypersensitivity reactions (e.g., anaphylaxis, angioedema), seizures, and certain cardiac events (e.g., QT prolongation, changes in heart rhythm). Instances of hepatitis and jaundice have also been reported.

Population-Specific Precautions:

Seizures: Caution is advised in patients with a personal or familial history of seizures, particularly young children, who may be more susceptible to new-onset seizures while on treatment. Healthcare providers may consider discontinuing the medication if a seizure occurs.
Kidney/Liver Impairment: Desloratadine should be used with caution in patients with severe renal or hepatic insufficiency, as exposure to the drug may be increased.
Pregnancy/Lactation: Use is generally not recommended during pregnancy or breastfeeding. Desloratadine has been identified in breastfed infants, and the potential effect on the infant is unknown.

Driving and Operating Machinery: Based on clinical trials, the drug has no or negligible influence on the ability to drive; however, individual response varies. Patients should ensure they do not experience drowsiness before engaging in activities requiring mental alertness. Caution is also recommended with the concomitant use of alcohol.

Overdose and Emergency Response

Overdose and When to Seek Help

This section describes the officially documented manifestations of desloratadine overdose and the actions mandated by regulatory authorities. The information is based strictly on the content of government-approved prescribing information and labeling.

Documented Clinical Manifestations

Clinical studies involving doses up to nine times the typical daily amount have documented specific manifestations associated with overdose. These officially recognized signs include somnolence (drowsiness), headache, and an increased heart rate (tachycardia). Although generally well-tolerated, the possibility of serious adverse cardiac events cannot be excluded in cases of massive exposure, emphasizing the need for professional evaluation.

Emergency Actions and Management

In the event of a suspected or confirmed overdose, regulatory guidance strictly mandates that individuals contact a poison control center immediately or seek urgent medical attention without delay. Treatment for desloratadine overdose is officially defined as symptomatic and supportive, as no specific antidote is known.

Supportive procedural steps described in regulatory documents involve measures to remove any unabsorbed substance from the body, such as gastric lavage or the administration of activated charcoal. Furthermore, continuous close medical monitoring, including observation of the patient's cardiac status and vital signs, is required due to the potential for cardiovascular effects.

Therapeutic Uses of Hitaxa Fast

What Hitaxa Fast Treats: Main Uses and Benefits

Hitaxa Fast (Desloratadine) is commonly used to help with symptomatic relief from conditions characterized by symptoms related to inflammatory or irritative states. This medication is generally applied across therapeutic domains, including Allergic Rhinitis and Chronic Idiopathic Urticaria.

Key Therapeutic Focus

The drug is commonly used to help ease symptoms that may become intense or disruptive, such as those clustering around the nose and eyes—sneezing, runny nose, nasal itching, and itchy, watery eyes—as well as those affecting the skin, primarily intense itching (pruritus) and the related discomfort of recurrent wheals. This relief is relevant for managing both seasonal flare-ups (like hay fever) and perennial (year-round) manifestations.

The application is relevant in instances of patient distress, offering symptomatic relief that helps patients cope more steadily. This helps ease the overall symptom burden and may assist with maintaining functional stability for individuals during symptomatic periods.

Indications and Benefit

Hitaxa Fast is used in situations involving allergic rhinitis (seasonal and perennial) and Chronic Idiopathic Urticaria (hives). This use contributes to easing the overall symptom load and helps maintain a sense of stability when symptoms are more noticeable, supporting patients during difficult episodes.

Quick Fact: Relief for Intense Itching

Regulatory References

Label: DESLORATADINE tablet - DailyMed - NIH

Eligibility and Restrictions for Use

Official Eligibility Profile

Regulatory authorities define the eligibility for Hitaxa Fast (Desloratadine) through specific age limits, contraindications, and conditions that require caution.

Eligibility Status	Population/Condition
Allowed	Adults and adolescents 12 years of age and older (for tablets/ODTs).
Use Not Established	Children below 12 years of age (for 5 mg tablets/ODTs).
Contraindicated	Individuals with known hypersensitivity to Desloratadine, Loratadine (its precursor), or any excipients in the formulation.

Conditional Use and Restrictions

Use is officially restricted or requires special caution in certain adult populations due to altered drug exposure or medical history:

Organ Impairment: Patients with severe renal insufficiency or severe hepatic impairment must use the medicine with caution, as regulatory documents advise restricted use in these groups.
Risk Factors: Caution is advised for administration to patients with a medical or familial history of seizures.
Pregnancy/Lactation: Use during pregnancy is preferable to avoid as a precautionary measure. Use during lactation (breastfeeding) is not recommended because the active substance is known to be excreted in breast milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Hitaxa Fast, which contains Desloratadine, is primarily characterized by official documentation of pharmacokinetic interactions that increase drug exposure. These patterns are stated in regulatory prescribing information and relate to co-administration with specific drugs.

Documented Exposure-Modifying Interactions

Co-administration with the following medicines has been documented to result in increased plasma concentrations (exposure) of Desloratadine and its active metabolite. Regulatory sources confirm that these increases were not associated with clinically relevant changes in the safety profile during clinical studies.

Type	Specific Interacting Medicines
Antifungal	Ketoconazole
Macrolide Antibiotic	Erythromycin
H2-Receptor Antagonist	Cimetidine
SSRI Antidepressant	Fluoxetine

Mechanism of Action

How Hitaxa Fast works

Antagonism of Histamine H1-Receptors

The active substance functions as a selective antagonist of peripheral Histamine H1-receptors. By binding to these receptors on target cells, the mechanism suppresses the initial signaling sequence triggered by the endogenous chemical, histamine. This action directly results in the modulation of histamine-induced increases in vascular permeability and the associated tissue responses.

Modulation and Site of Action

Beyond primary H1-receptor blockade, the mechanism extends to modulate the release and activity of other chemical mediators involved in the secondary inflammatory cascade. This influences cascading molecular effects downstream of mediator release. The drug acts predominantly on peripheral physiological systems; due to limited transport across the blood-brain barrier, activity is confined primarily to peripheral H1-receptors, resulting in altered physiological parameters within those pathways.

Dosage and Administration Information

How to Use Hitaxa Fast: Administration Guidelines

Hitaxa Fast is intended for oral administration across its approved dosage forms, including the standard tablet and the Orally Disintegrating Tablet (ODT). The medicine is consistently taken once daily, a frequency established to provide a 24-hour administration interval for symptom control.

Standard Dosage and Frequency

For adults and adolescents 12 years of age and older, the standard regimen is 5 milligrams (mg) once daily. This dosage is applied across all approved indications, including allergic rhinitis and chronic idiopathic urticaria. The medicine may be administered without regard to meals, allowing flexibility in the timing of intake.

Administration Method

Oral Tablets and ODTs: The ODT formulation is designed to dissolve rapidly on the tongue and should be placed on the tongue immediately after the blister is opened. It may be swallowed with saliva, and can be taken with or without water.

Missed Dose: If a dose is missed, it should be taken as soon as it is remembered. However, patients must avoid taking a double dose to compensate for the skipped dose, and the standard once-daily schedule should be resumed the following day.

Population-Specific Use and Duration

Dosage adjustments are specified for adult patients with hepatic (liver) or renal (kidney) impairment. For these patients, the recommended starting schedule is a modified dose of 5 mg every other day (q48h).

Treatment duration is linked to the nature of the condition. For intermittent allergic rhinitis (symptoms less than 4 days a week or for less than 4 weeks), use is generally contingent on the presence of symptoms. For persistent allergic rhinitis (symptoms 4 days or more a week and for more than 4 weeks), continuous long-term use is typically followed.

Recent Clinical Evidence

Evidence for Use in Allergic Rhinitis (Seasonal and Perennial)

Research exploring how symptoms change over time in allergic rhinitis has primarily relied on short-term, randomized, controlled trials (RCTs). Many of these studies included a placebo comparison group. These studies were applied in research contexts involving fluctuating or unstable symptoms, such as hay fever (seasonal) and year-round (perennial) allergic conditions. Researchers examined outcomes related to physical discomfort, focusing on standardized scores that measure the severity of nasal problems—like sneezing, congestion, and a runny nose—as well as associated eye symptoms, such as itching or watering.

Studies conducted during periods of increased symptom activity reported patterns of change in the measured symptom scores within the observed populations. Findings describe patterns observed in the studies related to changes in the measured severity of these upper respiratory and eye symptoms. Research has explored these symptom patterns over defined time intervals, providing insight into short-term changes during flare-ups.

Long-term studies following patients for many months or years are not frequently reported in the core evidence base. Therefore, evidence is limited regarding the use of the medicine continuously over long periods for chronic allergic rhinitis management.

Evidence for Use in Chronic Idiopathic Urticaria (Hives)

This medicine was also evaluated in studies examining symptom intensity or variability for Chronic Idiopathic Urticaria (CIU), a condition characterized by fluctuating or episodic manifestations like persistent hives and itching. The evidence base here also consists mainly of short-term, controlled trials. Research examined outcomes capturing phases of heightened symptom activity, such as changes in the Pruritus Score (how intensely patients reported itching) and the Wheal Score (measuring the size and number of hives). Patient-reported outcomes describing perceived discomfort and functional limitations, such as difficulty sleeping, were also monitored.

Studies monitored responses over defined time intervals and reported patterns of change in the measured scores for both itching and the physical presence of hives within the observed populations. Research highlights measured differences during the study period, particularly when comparing the treatment group to the placebo group. These findings describe group patterns observed in the trials and contribute to the broader evidence landscape for managing conditions where symptoms may vary in intensity.

Long-Term Evidence and Follow-Up in Studies

The majority of pivotal research used to understand the core actions of the medicine involves trials with limited follow-up durations, typically observing responses over defined time intervals of two to six weeks. This means that the evidence largely contributes to understanding symptom patterns during relatively short-term use.

There is limited information for long-term outcomes that would clarify the effects of consistent, continuous use over many seasons or years. Research is ongoing to better characterize the stability of the measured changes and the potential for symptoms to return after use is stopped.

Evidence in Special Populations

Research has explored the use of the medicine across different age groups. While the primary trials focused on Adults and Adolescents (aged 12 years and older), dedicated studies were conducted for Children aged 6 to 11 years with allergic rhinitis.

Data for certain groups remain insufficient. For instance, there is limited information available for long-term outcomes in younger children, and comprehensive research describing the use and measured effects in the older adult population is generally less extensive compared to the primary adult population.

What the Research Landscape Still Leaves Uncertain

The evidence highlights what is known—and what is still uncertain—about this medicine. A primary limitation is that follow-up durations were limited in most key efficacy trials, meaning that long-term effects are not fully established.

Additionally, while subgroup findings are uncertain, the existing body of research does not extensively include head-to-head clinical trials comparing this medicine to every other second-generation antihistamine. Research does not determine whether an individual will respond similarly to the group patterns observed in the studies, as results apply only to the specific populations and conditions studied.

Frequently Asked Questions (FAQ)

Common questions about Hitaxa Fast (FAQ)

Q: Does the 'Fast' in Hitaxa Fast mean it works quicker than other antihistamines?

The 'Fast' in the name primarily refers to the orally disintegrating tablet (ODT) formulation, which is designed to dissolve quickly on the tongue for ease of use. The drug’s active ingredient is measured to begin its antihistaminic effect within 1 hour after a standard oral dose. Pharmacokinetic data suggests that the drug's concentration typically peaks in the bloodstream at approximately 3 hours after administration.

Q: Is it possible to take Hitaxa Fast for a skin rash (hives) that isn't caused by a known allergy?

Official product information states that the medicine is indicated for managing symptoms of Chronic Idiopathic Urticaria (CIU). This classification applies to chronic hives and related symptoms where the underlying cause is not known (idiopathic).

Q: Does Hitaxa Fast cause weight gain, which is sometimes mentioned with allergy medications?

Official safety documents list 'weight increased' and 'increased appetite' as adverse reactions observed in post-marketing reports. These effects are currently classified with a 'Not Known' frequency, meaning the frequency cannot be estimated from the available data.

Q: Is it true that Hitaxa Fast oral disintegrating tablets contain a source of phenylalanine (aspartame)?

Yes, the orally disintegrating tablet (ODT) formulation may contain aspartame. Regulatory documents contain information regarding this excipient due to its relevance for patients with Phenylketonuria (PKU).

Q: Can I take Hitaxa Fast only when I have symptoms, or does it need to be taken consistently?

The guidance for use is related to the type of allergic condition. For symptoms that occur only sometimes (intermittent allergic rhinitis), treatment is often contingent on the presence of symptoms. For symptoms that are constant (persistent allergic rhinitis), continuous long-term use is typically followed.

Q: Why do some people with a chronic skin condition use Hitaxa Fast?

The medicine is indicated for managing the symptoms associated with Chronic Idiopathic Urticaria (CIU), which is a persistent skin condition characterized by fluctuating hives and itching. Studies have examined outcomes related to the intensity of symptoms like itching and hives.

Q: Can Hitaxa Fast be used safely for long periods, like several months or a whole allergy season?

Treatment duration is often linked to the condition, such as persistent allergic rhinitis. However, the core research base used to understand the medicine’s actions typically involves clinical trials with limited follow-up, meaning extensive evidence for continuous, long-term use over many seasons is not fully established.

Q: Can Hitaxa Fast be used to help with allergy-related eye itching and watering?

Research evaluating the medicine’s use for allergic rhinitis examined outcomes related to eye symptoms. Official information indicates that studies reported patterns of change in the measured severity of ocular symptoms, such as itching, watering, and redness.

Q: Is it true that children sometimes have a different reaction (e.g., excitation) to antihistamines like Hitaxa Fast?

Official safety data lists 'psychomotor hyperactivity' and 'abnormal behaviour' as very rare adverse reactions in post-marketing reports, particularly for some populations. Official safety documents contain information regarding the use of the medicine in patients with a personal or family history of seizures.

Q: Has Hitaxa Fast been studied in patients with asthma or other respiratory conditions?

Studies have been conducted using this medicine in patients who have seasonal allergic rhinitis alongside concomitant mild to moderate asthma. This research was conducted to evaluate symptom patterns in the allergic rhinitis population who also had concomitant mild to moderate asthma.

Q: How quickly does the active ingredient in Hitaxa Fast reach its highest level in the body?

Pharmacokinetic data suggests that the drug’s concentration typically peaks in the bloodstream at approximately 3 hours after oral administration.

Q: Does the 'Fast' formulation mean it is absorbed into the body faster than a regular tablet?

The 'Fast' orally disintegrating tablet (ODT) is designed for rapid disintegration on the tongue. However, official pharmacokinetic studies indicate that the time to reach maximum concentration in the blood is similar for both the ODT and the standard tablet formulation.

Q: Can individuals with kidney problems or liver disease use Hitaxa Fast?

Official prescribing information contains information regarding use in patients with severe renal (kidney) or hepatic (liver) impairment, noting that overall drug exposure may be increased in these groups. A modified dose is specified for adult patients with this impairment.

How should Hitaxa Fast be stored and disposed of?

Storage and Disposal of Hitaxa Fast

The storage and disposal of Hitaxa Fast (desloratadine orally disintegrating tablets) must strictly follow the conditions specified in official regulatory labeling to maintain product stability and integrity.

Storage Requirements

Condition
Temperature	Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F). Do not store above 30 C (86 F).
Protection	The tablets must be protected from moisture and light.
Handling	The orally disintegrating tablet must be taken immediately after opening the blister.
Child Safety	Keep this medicine out of the sight and reach of children.

Disposal Instructions

Do not dispose of this medicine by throwing it into wastewater or household waste. Unused or expired medication must be discarded according to local environmental rules, typically by asking a pharmacist for proper disposal instructions.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.